JP2016507521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507521A5 JP2016507521A5 JP2015555498A JP2015555498A JP2016507521A5 JP 2016507521 A5 JP2016507521 A5 JP 2016507521A5 JP 2015555498 A JP2015555498 A JP 2015555498A JP 2015555498 A JP2015555498 A JP 2015555498A JP 2016507521 A5 JP2016507521 A5 JP 2016507521A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding protein
- sequence shown
- disease
- motomeko
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000023732 binding proteins Human genes 0.000 claims 31
- 108091008324 binding proteins Proteins 0.000 claims 31
- 102100035793 CD83 antigen Human genes 0.000 claims 30
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 30
- 239000000203 mixture Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 210000000056 organ Anatomy 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010028417 myasthenia gravis Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 3
- 108091035707 Consensus sequence Proteins 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000005965 immune activity Effects 0.000 claims 2
- 239000012642 immune effector Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 150000001875 compounds Chemical group 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759780P | 2013-02-01 | 2013-02-01 | |
| US61/759,780 | 2013-02-01 | ||
| PCT/AU2014/000066 WO2014117220A1 (en) | 2013-02-01 | 2014-01-31 | Anti-cd83 antibodies and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000340A Division JP2019076102A (ja) | 2013-02-01 | 2019-01-04 | 抗ｃｄ８３抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016507521A JP2016507521A (ja) | 2016-03-10 |
| JP2016507521A5 true JP2016507521A5 (enExample) | 2017-02-23 |
| JP6539585B2 JP6539585B2 (ja) | 2019-07-03 |
Family
ID=51261317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555498A Active JP6539585B2 (ja) | 2013-02-01 | 2014-01-31 | 抗ｃｄ８３抗体及びその使用 |
| JP2019000340A Pending JP2019076102A (ja) | 2013-02-01 | 2019-01-04 | 抗ｃｄ８３抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000340A Pending JP2019076102A (ja) | 2013-02-01 | 2019-01-04 | 抗ｃｄ８３抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9840559B2 (enExample) |
| EP (2) | EP3626743A1 (enExample) |
| JP (2) | JP6539585B2 (enExample) |
| KR (2) | KR102449868B1 (enExample) |
| CN (1) | CN105531289B (enExample) |
| AU (1) | AU2014213009B2 (enExample) |
| CA (1) | CA2899960C (enExample) |
| DK (1) | DK2951208T3 (enExample) |
| ES (1) | ES2762622T3 (enExample) |
| MX (1) | MX2015010023A (enExample) |
| NZ (1) | NZ711543A (enExample) |
| PT (1) | PT2951208T (enExample) |
| WO (1) | WO2014117220A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015010023A (es) | 2013-02-01 | 2017-11-17 | Transbio Ltd | Anticuerpos anti-cd83 y su uso. |
| AU2015336931B2 (en) * | 2014-10-23 | 2021-04-29 | Kira Biotech Pty Limited | CD83 binding proteins and uses thereof |
| JP2020533384A (ja) * | 2017-09-13 | 2020-11-19 | キラ バイオテック ピーティーワイ リミテッド | 治療方法 |
| US12492254B2 (en) * | 2018-02-23 | 2025-12-09 | H. Lee Moffitt Cancer Center and Research Intitute. Inc. | CD83-binding chimeric antigen receptors |
| EP4004051A4 (en) | 2019-07-19 | 2023-08-23 | Oncoresponse, Inc. | IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOF |
| EP4013447A4 (en) * | 2019-08-16 | 2024-05-29 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING REGULATORY T CELLS |
| CN117547553A (zh) * | 2023-11-21 | 2024-02-13 | 中国人民解放军陆军特色医学中心 | Cd83+、cd83+pd-l1+间充质干细胞及其制备方法和应用 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4593089A (en) | 1980-07-30 | 1986-06-03 | Abbott Laboratories | Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4751190A (en) | 1985-07-22 | 1988-06-14 | Abbott Laboratories | Fluorescence polarization immunoassay and reagents for use therein |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1987006610A1 (en) | 1986-04-28 | 1987-11-05 | Endotronics, Inc. | Method of culturing leukocytes |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| DE4211351A1 (de) | 1992-04-04 | 1993-10-07 | Behringwerke Ag | Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung |
| EP0569141A3 (en) | 1992-04-14 | 1994-10-26 | Hybritech Inc | Method for inhibiting the growth of multidrug-resistant tumors by antibodies. |
| US5316920A (en) | 1992-04-17 | 1994-05-31 | Dana-Faber Cancer Institute, Inc. | Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily |
| US5710262A (en) | 1992-04-17 | 1998-01-20 | Dana-Faber Cancer Institute, Inc. | Nucleic acid encoding HB15 polypeptides |
| US20080152586A1 (en) | 1992-09-25 | 2008-06-26 | Avipep Pty Limited | High avidity polyvalent and polyspecific reagents |
| EP1550729B1 (en) | 1992-09-25 | 2009-05-27 | Avipep Pty Limited | Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain |
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6541213B1 (en) | 1996-03-29 | 2003-04-01 | University Of Washington | Microscale diffusion immunoassay |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| CA2244326C (en) | 1997-08-11 | 2006-03-28 | Shinichi Eda | Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| US6562622B1 (en) | 1998-05-08 | 2003-05-13 | Diatech Pty, Ltd | Continuous in vitro evolution |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| CA2360044A1 (en) | 1999-01-15 | 2000-07-20 | Medtox Scientific, Inc. | Lateral flow test strip |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0009772A (pt) * | 1999-04-14 | 2002-01-08 | Us Health | Composições contendo imunotoxinas e agentes que inibem a maturação de células dendrìticas para induzir tolerância imune a um enxerto |
| US7270969B2 (en) | 1999-05-05 | 2007-09-18 | Phylogica Limited | Methods of constructing and screening diverse expression libraries |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| JP4264348B2 (ja) | 2001-08-20 | 2009-05-13 | プロテオム システムズ リミテッド | 診断検査方法および装置 |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
| CA2466845A1 (en) | 2001-11-21 | 2003-06-05 | Fred Ramsdell | Manipulation of cytokine levels using cd83 gene products |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| AU2002950779A0 (en) | 2002-08-15 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of immunomodulation |
| US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| JP2006507510A (ja) | 2002-11-21 | 2006-03-02 | インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 組織低酸素症の体液マーカー |
| ATE481422T1 (de) * | 2002-11-21 | 2010-10-15 | Celltech R & D Inc | Modulieren von immunantworten |
| US7169898B2 (en) * | 2002-12-04 | 2007-01-30 | Alexander Steinkasserer | Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| CN1822857A (zh) | 2003-06-02 | 2006-08-23 | 阿莱克申药物公司 | 去免疫原性抗cd3抗体 |
| ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006063150A2 (en) * | 2004-12-08 | 2006-06-15 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| WO2006102720A1 (en) | 2005-03-31 | 2006-10-05 | Telethon Institute For Child Health Research | Isolation of inhibitor of ires-mediated translation |
| CA2602434C (en) * | 2005-04-08 | 2016-06-07 | Argos Therapeutics, Inc. | Dendritic cell compositions and methods |
| AU2006281980A1 (en) | 2005-08-15 | 2007-02-22 | Cephalon Australia Pty Ltd | Engineered antibodies with new world primate framework regions |
| CA2690973A1 (en) * | 2006-06-23 | 2007-12-27 | Paul M. Simon | Targeted immune conjugates |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| WO2009157623A1 (en) * | 2008-06-25 | 2009-12-30 | Korea Research Institute Of Bioscience And Biotechnology | Cd9-specific human antibodies |
| AR074369A1 (es) | 2008-11-20 | 2011-01-12 | Genentech Inc | Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso |
| EP2655415A4 (en) * | 2010-12-22 | 2016-03-09 | Abbvie Inc | THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF |
| JP2013040160A (ja) * | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| MX2015010023A (es) * | 2013-02-01 | 2017-11-17 | Transbio Ltd | Anticuerpos anti-cd83 y su uso. |
| AU2015336931B2 (en) | 2014-10-23 | 2021-04-29 | Kira Biotech Pty Limited | CD83 binding proteins and uses thereof |
| JP2020533384A (ja) | 2017-09-13 | 2020-11-19 | キラ バイオテック ピーティーワイ リミテッド | 治療方法 |
-
2014
- 2014-01-31 MX MX2015010023A patent/MX2015010023A/es active IP Right Grant
- 2014-01-31 KR KR1020207029681A patent/KR102449868B1/ko active Active
- 2014-01-31 EP EP19203675.4A patent/EP3626743A1/en not_active Withdrawn
- 2014-01-31 JP JP2015555498A patent/JP6539585B2/ja active Active
- 2014-01-31 AU AU2014213009A patent/AU2014213009B2/en not_active Ceased
- 2014-01-31 EP EP14745637.0A patent/EP2951208B1/en active Active
- 2014-01-31 WO PCT/AU2014/000066 patent/WO2014117220A1/en not_active Ceased
- 2014-01-31 DK DK14745637.0T patent/DK2951208T3/da active
- 2014-01-31 PT PT147456370T patent/PT2951208T/pt unknown
- 2014-01-31 ES ES14745637T patent/ES2762622T3/es active Active
- 2014-01-31 NZ NZ711543A patent/NZ711543A/en not_active IP Right Cessation
- 2014-01-31 CA CA2899960A patent/CA2899960C/en active Active
- 2014-01-31 KR KR1020157023660A patent/KR102204127B1/ko not_active Expired - Fee Related
- 2014-01-31 US US14/765,236 patent/US9840559B2/en active Active
- 2014-01-31 CN CN201480011458.5A patent/CN105531289B/zh active Active
-
2017
- 2017-11-09 US US15/808,423 patent/US10781255B2/en active Active
-
2019
- 2019-01-04 JP JP2019000340A patent/JP2019076102A/ja active Pending
-
2020
- 2020-07-09 US US16/924,860 patent/US11725054B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI883026B (zh) | 抗ｄｌｌ３嵌合抗原受體及其用途 | |
| JP2016507521A5 (enExample) | ||
| JP2023071684A (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP2012501670A5 (enExample) | ||
| CN112955470A (zh) | 抗tnfr2抗体及其用途 | |
| CN109563170B (zh) | 抗gitr抗体及其用途 | |
| TW201031421A (en) | IL-1 binding proteins | |
| WO2018137576A1 (zh) | 抗pd-1单克隆抗体及其制备方法和应用 | |
| JP2012526558A5 (enExample) | ||
| KR20180083944A (ko) | 항체 및 이의 사용 방법 | |
| TW201134487A (en) | Therapeutic DLL4 binding proteins | |
| JP2017530119A (ja) | リンパ球における阻害経路の中和 | |
| KR20120104542A (ko) | Ｉｌ?１ 결합 단백질 | |
| CN101512008A (zh) | 白介素-13结合蛋白 | |
| ES2737307T3 (es) | Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer | |
| US12071479B2 (en) | Antibodies against ILT2 and use thereof | |
| AU2020328931A1 (en) | Antibodies against ILT2 and use thereof | |
| CN113278071B (zh) | 抗人干扰素α受体1单克隆抗体及其应用 | |
| CA3172120A1 (en) | Chimeric antigen receptor specific for human cd45rc and uses thereof | |
| US20240010751A1 (en) | Multispecific binding agents and uses thereof | |
| CN109071660A (zh) | 预防移植物抗宿主疾病的方法 | |
| WO2022031680A1 (en) | Cd47 binding agents and uses thereof | |
| US20230303699A1 (en) | Pd-l1 binding agents and uses thereof | |
| JP2024512252A (ja) | Ｃｄ４７に対する単一ドメイン抗体及びその用途 | |
| HK1229347A1 (en) | Therapeutic dll4 binding proteins |